Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your Swiss-Rx-Login. For further information please see the FAQ.
RYBREVANT Inf Konz 350 mg/7ml
Drug
Rybrevant, Konzentrat zur Herstellung einer Infusionslösung
nicht-kleinzelliges Lungenkarzinom (NSCLC)
07.16.1. – cytostatics
HAM – Human medicine
KOINF – Concentrate for solution for infusion
BT – biological medicines
A – Dispensed once only on prescription by a physician or veterinarian (A)
Z – approved
1/20/2022
5/1/2029
Dosage strength
Rybrevant 350 mg/7 ml, Konzentrat zur Herstellung einer Infusionslösung
nicht-kleinzelliges Lungenkarzinom (NSCLC)
01
Z – approved
Package
7680683800017
Out of trade from / since 5/31/2024
A/R – Authorised / referenced
1 vial(s)
001
Z – approved
Declaration
Component
350 mg amivantamabum
histidinum
histidini hydrochloridum monohydricum
saccharum
polysorbatum 80
dl-methioninum
dinatrii edetas
aqua ad iniectabile
17 µg natrium
histidini hydrochloridum monohydricum
saccharum
polysorbatum 80
dl-methioninum
dinatrii edetas
aqua ad iniectabile
17 µg natrium
Spezialitätenliste***
SL
-
-
1343.95
None
Yes
10%
No
Authorisation holder
7601001000902
Janssen-Cilag AG
Gubelstrasse 34
6300 Zug (ZG)
Gubelstrasse 34
6300 Zug (ZG)
Date of revision of the text
7/4/2024
Please log in as a company employee using your Swiss-Rx-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.